. GSK (LSE: GSK) The price of shares gained 3% in early trade on Wednesday (April 30), as the pharmaceutical giant told usWell prepared to respond to the potential financial impact of the tariff for the sector. “

The assurance took place in the update in the first quarter, because the company talked about “Options of alleviating identified in the initiatives of the supply chain and productivity.“

The actions fell sharply in the days after the first announcement of President Trump’s tariffs. And although the price has recovered after this inheritance, so far it has dropped by 11%.

Special Drugs

GSK recorded an escalate in revenues by 2% at actual exchange rates (4% at a constant pace), powered largely by a 17% escalate in sales in the specialist medicine department. This helped compensate for the disappointing drop in sales of vaccines by 6%, with its sale Shinggrix Vaccine anti -tubes dropped by 7%. Basic profit per share (EPS) increased by 5%.

After seeing the cash generated from the operation of 1.3 billion pounds, the company announced a dividend of 16 pence per share, including quarter. Unless something drastic happens, I think we can be quite sure of the expected all dividend in the amount of 64p. On the previous day this would mean a dividend performance of 4.5%.

On the subject of research and development, the general director of Emma Walmsley talked about “Two of five permits for FDA products expected this year have been secured.“The company is preparing for”Launching Blenrep, Nucala and Depemokimab and key studies on potential new respiratory, oncology, HIV and hepatitis. “

The boss added that all this helps “”They are at the root of our trust in the tips for a year and our long -term prospectsS. “

Investing perspectives

In the case of such a company, it is really long -term research and drug development makes a difference. Ten years ago, GSK and RIVER Astrasenec They stood in the face of the losses of the hit patents for drugs with a tiny amount of exchange on the horizon. It took them a long time to start the pipeline again. And a arid spell probably caused more brief -term damage to shareholders than probably any Donald Trump tariff.

In this result, GSK looks nice now. And I really wonder why the price of the campaign reflects such a seemingly low quote. We look at the price -profit ratio below 10 based on current 2025 forecasts. And it can drop to about 8.2 to 2027 if the expectations regarding the escalate in earnings are good.

For comparison, Astrazeneca has a forward 24, falling to 17, on the same time scale. The expected GSK dividend performance is twice as high as Astrazeneca.

Uncertain perspectives

However, it is complex to realistically compare such valuations, because some drugs can be much more profits than others. And despite the GSK bravado, I am afraid that the uncertain trade war can for some time maintain the price of shares under pressure.

But I evaluate it as FTSE 100 The company is worth considering for investors who look further.